![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
References
- Galliher AJ, Neil JR, Schiemann WP. Role of transforming growth factor-β in cancer progression. Future Oncol.2, 743–763 (2006).
- Neil JR, Galliher AJ, Schiemann WP. TGF-β in cancer and other diseases. Future Oncol.2, 185–189 (2006).
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100, 57–70 (2000).
- Massague J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell103, 295–309 (2000).
- Elliott RL, Blobe GC. Role of transforming growth factor-β in human cancer. J. Clin. Oncol.23, 2078–2093 (2005).
- Bhowmick NA, Chytil A, Plieth D et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science303, 848–851 (2004).
- Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature432, 332–337 (2004).
- Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signaling inhibitors for cancer therapy. Nat. Rev. Drug Discov.3, 1011–1022 (2004).
- Sokol JP, Neil JR, Schiemann BJ, Schiemann WP. The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-β. Breast Cancer Res.7, R844 (2005).
- Sokol JP, Schiemann WP. Cystatin C antagonizes transforming growth factor-β signaling in normal and cancer cells. Mol. Cancer Res.2, 183–195 (2004).
- Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/α 2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist. J. Biol. Chem.271, 12755–12761 (1996).
- Swallow CJ, Partridge EA, Macmillan JC et al. α2-HS glycoprotein, an antagonist of transforming growth factor β in vivo, inhibits intestinal tumor progression. Cancer Res.64, 6402–6409 (2004).
- Ge R, Rajeev V, Ray P et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-β type I receptor kinase in vivo.Clin. Cancer Res.12, 4315–4330 (2006).
- Moustakas A, Heldin CH. Non-Smad TGF-β signals. J. Cell Sci.118, 3573–3584 (2005).
- Galliher AJ, Schiemann WP. β3 integrin and Src facilitate transforming growth factor-β mediated induction of epithelial–mesenchymal transition in mammary epithelial cells. Breast Cancer Res.8, R42 (2006).
- Galliher AJ, Schiemann WP. Src phosphorylates Tyr284 in TβR-II and regulates TGF-β stimulation of p38 MAP kinase during breast cancer cell proliferation and invasion. Cancer Res. (2007) (In Press).